Trial Profile

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Atezolizumab in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; EIK 1001 (Primary)
Indications Carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions
Acronyms EIK1001
Sponsors Eikon Therapeutics

Most Recent Events

26 Mar 2025 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
28 May 2024 According to an Eikon Therapeutics media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31-June 4, 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com